We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma (Shelter)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00943449
Recruitment Status : Completed
First Posted : July 22, 2009
Last Update Posted : January 16, 2014
Information provided by:

Brief Summary:
The purpose of the study is to determine whether 4SC-201 alone or in combination with Sorafenib is effective and safe in the treatment of hepatocellular carcinoma in patients refractory to Sorafenib monotherapy.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: 4SC-201 Drug: Sorafenib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment
Study Start Date : July 2009
Actual Primary Completion Date : June 2012
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Sorafenib

Arm Intervention/treatment
Experimental: 4SC-201 Drug: 4SC-201
oral administration

Experimental: 4SC-201 + Sorafenib Drug: 4SC-201
oral administration

Drug: Sorafenib
oral administration

Primary Outcome Measures :
  1. Progression Free Survival Rate (PFSR) of repeated oral doses of 4SC-201 and of the treatment combination of Sorafenib plus 4SC-201 [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. To establish the MTD of 4SC-201 in combination with Sorafenib [ Time Frame: 12 weeks ]
  2. To investigate the safety and tolerability of repeated oral doses of 4SC-201 and of the treatment combination of ascending repeated oral doses of 4SC-201 and Sorafenib [ Time Frame: 12 weeks ]
  3. To investigate biomarkers [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Advanced stage hepatocellular carcinoma
  • Patients exhibiting progressive disease under Sorafenib treatment
  • Child-Pugh class A and B. Only patients with Child-Pugh index class B of not more than 7 will be included
  • ECOG performance status 0, 1 or 2
  • Precedent first-line treatment with Sorafenib minimum continuous dosing of 400 mg per day for at least 8 weeks

Main Exclusion Criteria:

  • Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1) - any cancer curatively treated > 3 years prior to entry is permitted
  • Renal failure requiring hemo- or peritoneal dialysis
  • Known central nervous system (CNS) tumors including symptomatic brain metastasis
  • Child-Pugh index class B in combination with more than slight ascites or hepatic encephalopathy > Grade I
  • Pregnant or breastfeeding women
  • Sorafenib intolerance
  • Major surgery within the last 4 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00943449

Layout table for location information
ONKOPLUS Beratung und Hilfe für Menschen mit Krebs
Berlin, Germany, 14195
Universitätsklinikum Essen (Innere Klinik/Tumorforschung und Zentrum für Innere Medizin)
Essen, Germany, 45147
Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg (Klinik und Poliklinik für Innere Medizin I)
Halle, Germany, 06120
Universitätsklinikum Hamburg-Eppendorf (I. Medizinische Klinik und Poliklinik)
Hamburg, Germany, 20246
Universitätsklinikum Heidelberg (Medizinische Universitätsklinik/Innere Medizin IV/Nationales Centrum für Tumorerkrankungen)
Heidelberg, Germany, 69120
Johannes Gutenberg-Universität Mainz (I. Medizinische Klinik und Poliklinik)
Mainz, Germany, 55131
Klinikum rechts der Isar der Technischen Universität München (Medizinische Klinik und Poliklinik II/Gastroenterologie)
Munich, Germany, 81675
Universitätsklinikum Tübingen (Medizinische Klinik/Innere Medizin I)
Tübingen, Germany, 72076
l'Azienda Ospedaliero-Universitaria di Bologna-Policlinico S. Orsola Malpighi
Bologna, Italy, 40138
l'Università degli Studi di Genova (Dipartimento di Medicina Interna e Specialità Mediche)
Genova, Italy, 16132
Istituto Europea di Oncologia EIO
Milano, Italy, 20141
A.O.R.N. Monaldi-Cotugno-CTO
Napoli, Italy, 80131
l'Azienda Ospedaliera di Padova and l'Istituto Oncologico Veneto IOV
Padova, Italy
l'Ente "Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone"
Palermo, Italy, 12990127
L'Istituto Clinico Humanitas-Humanitas Mirasole S.p.A.
Rozzano-Milano, Italy, 20089
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Michael Bitzer, Prof. MD Medizinische Universitäts-Klinik Tübingen
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00943449    
Other Study ID Numbers: 4SC-201-1-2009
First Posted: July 22, 2009    Key Record Dates
Last Update Posted: January 16, 2014
Last Verified: January 2014
Keywords provided by 4SC AG:
Hepatocellular Carcinoma
Phase II
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action